In a substudy of the LEAN trial that included 14 patients, liraglutide significantly reduced low-density lipoprotein (LDL)-cholesterol, ALT, serum leptin, adiponectin, and CCL-2 concentrations (all p 10%), the 24-week effect of treatment with 10 g exenatide and insulin glargine twice daily was compared [48]
Tirzepatide, also known by the brand names Mounjaro and Zepbound, is an FDA-approved dual-action GLP-1/GIP receptor agonist made by Eli Lilly
When used consistently, it can also improve longer-term markers like A1C, which is the average level of blood sugar over two to three months
Safety Considerations and Provider Evaluation for Non-Overweight Patients Non-overweight patients starting GLP-1 therapy require the same safety monitoring as any candidate: baseline kidney function, liver panels, and screening for personal or family history of thyroid cancer or medullary thyroid carcinoma
Our team is here to guide and support you every step of the way, ensuring a comprehensive approach to your long-term health and well-being